OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

The Future of RET Inhibitors in Non-Small Cell Lung and Thyroid Cancer

home / insights / ret-inhibitors-nsclc-thyroid-cancer
Advertisement
Why RET Alteration is an Attractive Target for Therapy

EP. 1: Why RET Alteration is an Attractive Target for Therapy

October 18th 2019
RET Fusion, Point Mutation, and Signaling

EP. 2: RET Fusion, Point Mutation, and Signaling

October 18th 2019
Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

EP. 3: Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

October 18th 2019
RET Treatment: Novel Compounds to Replace Current TKIs

EP. 4: RET Treatment: Novel Compounds to Replace Current TKIs

October 18th 2019
The Importance of NGS Testing

EP. 5: The Importance of NGS Testing

October 18th 2019
RET Testing in Papillary and Medullary Thyroid Cancer

EP. 6: RET Testing in Papillary and Medullary Thyroid Cancer

October 18th 2019
Advertisement
LIBRETTO-001 Regimen Overview

EP. 7: LIBRETTO-001 Regimen Overview

October 18th 2019
LOXO-292 in Patients With RET-Fusion Lung Cancer

EP. 8: LOXO-292 in Patients With RET-Fusion Lung Cancer

October 18th 2019
ESMO 2019 LIBRETTO-001 Trial Updates

EP. 9: ESMO 2019 LIBRETTO-001 Trial Updates

October 18th 2019
How BLU-667 Has Changed the Treatment Landscape

EP. 10: How BLU-667 Has Changed the Treatment Landscape

October 18th 2019
RET Inhibitor Trial Updates at ASCO and ESMO

EP. 11: RET Inhibitor Trial Updates at ASCO and ESMO

October 18th 2019
Using RET Inhibitors in Clinical Practice

EP. 12: Using RET Inhibitors in Clinical Practice

October 18th 2019
Advertisement
The Next Steps in RET Inhibitor Research

EP. 13: The Next Steps in RET Inhibitor Research

October 18th 2019
Notable RET Inhibitor Trials Underway

EP. 14: Notable RET Inhibitor Trials Underway

October 18th 2019

Latest Conference Coverage

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

Dr Hoppe on the Rationale for the CheckMate 744 Trial in Hodgkin Lymphoma

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact